BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and
treatment interruption. The aim of these clinical standards is to encourage best practise for …

SETTING: Active pharmacovigilance (PV) is recommended for TB programmes, notably for
multidrug-resistant TB (MDR-TB) patients treated with new drugs. Launched with the support …

Background New medicines have become available for the treatment of drug-resistant
tuberculosis (DR-TB) and are introduced in sub-Saharan Africa (SSA) by the national TB …

Background World Health Organization (WHO) recommends that active TB Dug Safety
Monitoring and Management (aDSM) be adopted in countries' programmatic management …

Аннотация Введение. При клинической манифестации туберкулеза легких
альвеолярные макрофаги накапливают микобактерии и перестают выполнять свои …

BACKGROUND: Drug-resistant tuberculosis (DR-TB) remains a global public health crisis.
In 2013, the World Health Organization recommended the introduction of bedaquiline (BDQ) …

Key Messages The introduction of novel medicines and regimens for antiretroviral (ARV)
and TB treatment requires comprehensive surveillance systems for adverse events and …

Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption.
The aim of these clinical standards is to encourage best practise for the diagnosis and …

Tuberculosis (TB) is a disease caused by Koch's bacillus. It is the ninth leading cause of
death worldwide, and the most common infectious cause of death, surpassing HIV/AIDS …